| Gene Symbol | MAPT |
| Full Name | Microtubule-Associated Protein Tau |
| Aliases | H1/H2 |
| Chromosome | 17q21.31 |
| Protein Type | Structural Protein |
| Target Class | Structural Protein |
| Function | Tau aggregation inhibitors, anti-tau antibodies, tau phosphorylation modulators |
| Mechanism of Action | Tau aggregation inhibitors, anti-tau antibodies, tau phosphorylation modulators |
| Druggability | Medium (0.45) |
| Clinical Stage | Phase III |
| Molecular Weight | 65 kDa |
| Amino Acids | 441 aa |
| Exons | 16 |
| Pathways | Amyloid, Apoptosis, Autophagy, Camp Signaling, Cholesterol |
| UniProt ID | A0A7I2PJZ2 |
| GeneCards | MAPT |
| Human Protein Atlas | MAPT |
| Associated Diseases | AD, Ad Pathology, Aging, Als, Alzheimer |
| Known Drugs/Compounds | 13G4, anti-tau antibodies, berberine, Flavonoids, HSP90 inhibitors, Rutin |
| Interactions | A2M, ACE, ACHE, Actin, AD, AGING |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | Microglial-Mediated Tau Clearance Dysfunction via Glymphatic-Mediated Tau Clearance Dysfunction MAPT tau seeding and release across AD, FTD, and P (+40 more) |
| KG Connections | 2023 knowledge graph edges |
| Databases | GeneCardsNCBI GeneHPASTRING |
No AI portrait yet
No comments yet. Be the first to comment!